IP And Trademarks 25 September 2026
Guggenheim Boosts Travere Therapeutics Target After Patent Grant
Analysts at Guggenheim have increased their price target for Travere Therapeutics following the grant of a method‑of‑use patent for its IgA nephropathy treatment, which extends protection through October 2037. The new target reflects confidence that the patent will bolster the drug’s market potential and supports the stock’s recent upward momentum.
Guggenheim raised its price target for Travere Therapeutics after the company secured a method‑of‑use patent for its IgA nephropathy drug, extending protection to October 2037.
- Patent grant strengthens commercial outlook
- Target increase signals confidence in drug’s market potential
- Stock has shown recent gains following the news
Read the full report on Investing.com.
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.